CYP11, CYP17, CYP19, CYP20 and CYP21 families | Enzymes

CYP11, CYP17, CYP19, CYP20 and CYP21 families C

Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).

GtoImmuPdb view: OFF

Enzymes

CYP11A1 C Show summary »« Hide summary More detailed page

Target Id

1358

Nomenclature

CYP11A1

Previous and unofficial names

Genes

CYP11A1 (Hs), Cyp11a1 (Mm), Cyp11a1 (Rn)

Ensembl ID

ENSG00000140459 (Hs), ENSMUSG00000032323 (Mm), ENSRNOG00000008074 (Rn)

UniProtKB AC

P05108 (Hs), Q9QZ82 (Mm), P14137 (Rn)

EC number

1.14.15.6

Inhibitors

mitotane [5-6]

Comment

Converts cholesterol to pregnenolone plus 4-methylpentanal.

CYP11B1 C Show summary »« Hide summary More detailed page

Target Id

1359

Nomenclature

CYP11B1

Previous and unofficial names

Genes

CYP11B1 (Hs), Cyp11b1 (Mm), Cyp11b1 (Rn)

Ensembl ID

ENSG00000160882 (Hs), ENSMUSG00000075604 (Mm), ENSRNOG00000032450 (Rn)

UniProtKB AC

P15538 (Hs), P15393 (Rn)

EC number

1.14.15.4

Inhibitors

metyrapone pIC₅₀ 7.8 [16]

mitotane

Comment

Converts deoxycortisone and 11-deoxycortisol to cortisone and cortisol, respectively. Loss-of-function mutations are associated with familial adrenal hyperplasia and hypertension. Inhibited by metyrapone [14]

Aldosterone synthase (CYP11B2) C Show summary »« Hide summary More detailed page

Target Id

1360

Nomenclature

CYP11B2

Common abbreviation

Aldosterone synthase

Previous and unofficial names

Genes

CYP11B2 (Hs), Cyp11b2 (Mm), Cyp11b2 (Rn)

Ensembl ID

ENSG00000179142 (Hs), ENSMUSG00000022589 (Mm), ENSRNOG00000030111 (Rn)

UniProtKB AC

P19099 (Hs), P15539 (Mm), P30099 (Rn), P30100 (Rn)

EC number

1.14.15.4

1.14.15.5

Inhibitors

osilodrostat pIC₅₀ 9.7 [15]

Comment

Converts corticosterone to aldosterone

CYP17A1 C Show summary »« Hide summary More detailed page

Aromatase (CYP19A1) C Show summary »« Hide summary More detailed page

CYP20A1 C Show summary »« Hide summary

CYP21A2 C Show summary »« Hide summary

References

Show »« Hide

1. Bhatnagar AS, Häusler A, Schieweck K, Lang M, Bowman R. (1990) Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J. Steroid Biochem. Mol. Biol., 37 (6): 1021-7. [PMID:2149502]

2. Christiansen JS. (1985) Glomerular hyperfiltration in diabetes mellitus. Diabet. Med., 2 (4): 235-9. [PMID:2951074]

3. Covey DF, Hood WF. (1982) A new hypothesis based on suicide substrate inhibitor studies for the mechanism of action of aromatase. Cancer Res., 42 (8 Suppl): 3327s-3333s. [PMID:7083195]

4. Handratta VD, Vasaitis TS, Njar VC, Gediya LK, Kataria R, Chopra P, Newman Jr D, Farquhar R, Guo Z, Qiu Y et al.. (2005) Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J. Med. Chem., 48 (8): 2972-84. [PMID:15828836]

5. Lehmann TP, Wrzesiński T, Jagodziński PP. (2013) The effect of mitotane on viability, steroidogenesis and gene expression in NCI‑H295R adrenocortical cells. Mol Med Rep, 7 (3): 893-900. [PMID:23254310]

6. Libè R, Fratticci A, Bertherat J. (2007) Adrenocortical cancer: pathophysiology and clinical management. Endocr. Relat. Cancer, 14 (1): 13-28. [PMID:17395972]

7. Mayhoub AS, Marler L, Kondratyuk TP, Park EJ, Pezzuto JM, Cushman M. (2012) Optimization of the aromatase inhibitory activities of pyridylthiazole analogues of resveratrol. Bioorg. Med. Chem., 20 (7): 2427-34. [PMID:22386564]

8. Muftuoglu Y, Mustata G. (2010) Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg. Med. Chem. Lett., 20 (10): 3050-64. [PMID:20413308]

9. Payne EJ, Ingley E, Dick IM, Wilson SG, Bond CS, Prince RL. (2009) In vitro kinetic properties of the Thr201Met variant of human aromatase gene CYP19A1: functional responses to substrate and product inhibition and enzyme inhibitors. J. Clin. Endocrinol. Metab., 94 (8): 2998-3002. [PMID:19470632]

10. Pinto-Bazurco Mendieta MA, Negri M, Jagusch C, Müller-Vieira U, Lauterbach T, Hartmann RW. (2008) Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer. J. Med. Chem., 51 (16): 5009-18. [PMID:18672868]

11. Plourde PV, Dyroff M, Dukes M. (1994) Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res. Treat., 30 (1): 103-11. [PMID:7949201]

12. Potter GA, Barrie SE, Jarman M, Rowlands MG. (1995) Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J. Med. Chem., 38 (13): 2463-71. [PMID:7608911]

13. Rotstein DM, Kertesz DJ, Walker KA, Swinney DC. (1992) Stereoisomers of ketoconazole: preparation and biological activity. J. Med. Chem., 35 (15): 2818-25. [PMID:1495014]

14. Watanuki M, Tilley BE, Hall PF. (1978) Cytochrome P-450 for 11beta- and 18-hydroxylase activities of bovine adrenocortical mitochondria: one enzyme or two?. Biochemistry, 17 (1): 127-30. [PMID:412519]

15. Yin L, Hu Q, Emmerich J, Lo MM, Metzger E, Ali A, Hartmann RW. (2014) Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors. J. Med. Chem., 57 (12): 5179-89. [PMID:24899257]

16. Zimmer C, Hafner M, Zender M, Ammann D, Hartmann RW, Vock CA. (2011) N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2). Bioorg. Med. Chem. Lett., 21 (1): 186-90. [PMID:21129965]

How to cite this family page

Database page citation:

CYP11, CYP17, CYP19, CYP20 and CYP21 families. Accessed on 12/07/2017. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=266.

Concise Guide to PHARMACOLOGY citation:

Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Southan C, Davies JA and CGTP Collaborators (2015) The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol. 172: 6024-6109.